Takeda's Actos Suspended On French, German Markets For Risks
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical's diabetes major drug, Actos (pioglitazone) has been suspended from the French and German markets because of an increased risk of bladder cancer